Regulatory Scrutiny Builds

Consumer immune-cell banking attracts scrutiny because the clinical utility for healthy customers remains unproven. Regulators do not ban the model, but they could restrict marketing claims, require clearer consent, and force higher compliance spending.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.